KRAS and cancer: The identification of HLA-C*08:02 restrictions for targeting KRAS G12D neoepitopes heralds an opportunity for potential therapy for common driver mutations in cancers.366 KRAS G12 mutations are commonly found in PDAC, CRC, and NSCLC.